Fig. 8.
![Fig. 8. In vivo tracking of BCL1 tumor in the spleen. / HuCD64+ mice received 2 μg murine G-CSF/d subcutaneously 4 days before tumor and continuing throughout the course of therapy (10 days in total). Mice were then inoculated with 107 BCL1 tumor cells intraperitoneally on day 0 and were treated with twice daily injections of 50 μg BsAb intraperitoneally on days 1 to 5 (500 μg/mouse in total). One animal per group was killed on days 5, 10, and 15, and the percentages tumor cells in spleen were determined using flow cytometry with PE-labeled anti-Id versus FITC-labeled anti-CD22. Shown are dot plots from a representative mouse at days 10 and 15, treated with BsAb of the specificities indicated. Control BsAb was the nonbinding [huCD64 × A31 Id].](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/96/10/10.1182_blood.v96.10.3544/5/h82200347008.jpeg?Expires=1725294239&Signature=j0aT1gaPo~u3U0kEyiBxT2TemFbcxKW~ajjodApNJXZnPIbJmyDSAiF95Fkc6GVi9UVLXz60Jmj6b3QW0DcPCJFbxr5rcKLzVS3VodmXLAILPxrnQOguNkk1t--vrZK-kTPr1T5oE8EiXMIGrR4F8LsdBp9nMLVzLuSTunsQ9E6UoSHabxybu8KO61tWOpfMortypAre7t8Lu1k3y-QzVjZ3mPDhOy5EsnfyocbOOP~duz~n5oiYLxvAGqjxCufTI~-qKvpqHqDhfGIEb5k8pLdudQvunap22mqa9Byzwv8O1cH~LNQTq9nhE5vQpTSZGL2lulJOg~obDFEe3J3rnA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
In vivo tracking of BCL1 tumor in the spleen.
HuCD64+ mice received 2 μg murine G-CSF/d subcutaneously 4 days before tumor and continuing throughout the course of therapy (10 days in total). Mice were then inoculated with 107 BCL1 tumor cells intraperitoneally on day 0 and were treated with twice daily injections of 50 μg BsAb intraperitoneally on days 1 to 5 (500 μg/mouse in total). One animal per group was killed on days 5, 10, and 15, and the percentages tumor cells in spleen were determined using flow cytometry with PE-labeled anti-Id versus FITC-labeled anti-CD22. Shown are dot plots from a representative mouse at days 10 and 15, treated with BsAb of the specificities indicated. Control BsAb was the nonbinding [huCD64 × A31 Id].
